Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/19/2003WO2003050254A2 Novel chimeric tnf ligands
06/19/2003WO2003050248A2 Adenine nucleotide-binding protein-directed probes and methods of their synthesis and use
06/19/2003WO2003050241A2 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
06/19/2003WO2003050190A2 Novel combination containing a poloxamer and chondroitin sulphuric acid and/or a glycoprotein and use thereof
06/19/2003WO2003050132A1 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials
06/19/2003WO2003050129A1 Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
06/19/2003WO2003050128A1 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
06/19/2003WO2003050124A1 Crystalline cefdinir potassium dihydrate
06/19/2003WO2003050122A2 Mitotic kinesin inhibitors
06/19/2003WO2003050121A1 Thioether substituted imidazoquinolines
06/19/2003WO2003050120A1 Pyrazolo-pyridine derivatives as antiherpes agents
06/19/2003WO2003050119A2 Urea substituted imidazopyridines
06/19/2003WO2003050118A1 Amide substituted imidazopyridines
06/19/2003WO2003050117A1 Sulfonamido substituted imidazopyridines
06/19/2003WO2003050116A1 A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
06/19/2003WO2003050110A1 Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
06/19/2003WO2003050109A1 Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
06/19/2003WO2003050108A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003WO2003050107A1 New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
06/19/2003WO2003050102A1 Novel compounds for the treatment of cardiac arrhythmia, synthesis, and methods of use
06/19/2003WO2003050101A1 Deuterated substituted dihydrofuranones and medicaments containing these compounds
06/19/2003WO2003050099A1 Phenylalkynes
06/19/2003WO2003050097A1 Sodium salt of benzyl thiazolidine-2,4-dione derivative and hydrate thereof
06/19/2003WO2003050095A1 Substituted benzoxazoles and analogues as estrogenic agents
06/19/2003WO2003050093A1 Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer
06/19/2003WO2003050091A1 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
06/19/2003WO2003050090A1 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
06/19/2003WO2003050085A1 CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1)
06/19/2003WO2003050077A1 Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same
06/19/2003WO2003050076A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003WO2003050075A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/19/2003WO2003050073A1 Substituted hydroxyethylamines
06/19/2003WO2003050072A1 Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
06/19/2003WO2003050067A2 Vitamin d analogues
06/19/2003WO2003050066A1 Functionalized higher diamondoids
06/19/2003WO2003050064A2 Mitotic kinesin inhibitors
06/19/2003WO2003050063A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE β-AMINO-ALCOHOLS
06/19/2003WO2003049804A2 Treatment of genitourinary tract disorders
06/19/2003WO2003049801A1 Photophoretic auto immune stimulation
06/19/2003WO2003049786A2 Metering valve and pharmaceutical metered dose inhaler and methods thereof
06/19/2003WO2003049774A1 Transdermal transport of compounds
06/19/2003WO2003049773A1 Methods for inhibiting ocular processes
06/19/2003WO2003049772A2 Guanidinium transport reagents and conjugates
06/19/2003WO2003049770A1 Use of an h1 antagonist and a safe steroid to treat rhinitis
06/19/2003WO2003049769A2 Method for reducing acne or improving skin tone
06/19/2003WO2003049768A1 Selective anesthetic agents and methods of identifying the same
06/19/2003WO2003049753A1 Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
06/19/2003WO2003049747A1 Pharmaceutical composition for use in ophthalmology and rhinology
06/19/2003WO2003049746A2 Combination of cytochome p450 dependent protease inhibitors
06/19/2003WO2003049745A1 Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
06/19/2003WO2003049744A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
06/19/2003WO2003049743A1 Combination cancer therapy
06/19/2003WO2003049742A1 Method for administering birb 796 bs
06/19/2003WO2003049741A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003WO2003049740A1 Quinazoline derivatives for the treatment of abnormal cell growth
06/19/2003WO2003049739A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003WO2003049738A1 Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
06/19/2003WO2003049734A1 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
06/19/2003WO2003049733A1 High-concentration stable meloxicam solutions for needle-less injection
06/19/2003WO2003049732A1 Use of 4-androstenediol and 4-androstenediol in a transdermal formulation to increase testosterone levels in humans
06/19/2003WO2003049731A1 Process for affecting neurologic progression
06/19/2003WO2003049730A1 Treatment of statin side effects using uridine derivatives
06/19/2003WO2003049729A1 Use of creatine and/or creatine derivatives in muscle impairments and/or muscle disorders not caused by illness
06/19/2003WO2003049728A1 Medium for radical treatment of tumors, inflammatory processes, fungal infections and other affections of the tissues, diagnostic and prophylactic and method of its implementation
06/19/2003WO2003049727A1 Treatment of neoplasia
06/19/2003WO2003049726A1 Respiratory infection prevention and treatment with terpene-containing compositions
06/19/2003WO2003049725A2 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
06/19/2003WO2003049724A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
06/19/2003WO2003049723A2 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
06/19/2003WO2003049721A1 Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
06/19/2003WO2003049720A1 Combination therapy comprising a cyclooygenase-2 inhibitor
06/19/2003WO2003049718A1 Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
06/19/2003WO2003049717A2 Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
06/19/2003WO2003049716A1 Stable topical formulation of clarithromycin
06/19/2003WO2003049713A1 Utilization of dihydropinosylvin and derivatives thereof as tyrosinase inhibitors for skin lightening or as antimicrobial substances for preservation or for the treatment of acne, dandruff or body odors
06/19/2003WO2003049709A1 Ceramide emulsions
06/19/2003WO2003049705A2 Use of pramipexole to treat amyotrophic lateral sclerosis
06/19/2003WO2003049702A2 Vanilloid receptor ligands and their use in treatments
06/19/2003WO2003049698A2 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003WO2003049697A2 Treatment of glioblastoma with thymosin-alpha 1
06/19/2003WO2003049696A2 Glucosamine organic acid adducts
06/19/2003WO2003049692A2 The use of acyl salicylates as heat shock inducers
06/19/2003WO2003049690A2 Hiv integrase inhibitors
06/19/2003WO2003049689A2 Isoflavone composition for oral delivery
06/19/2003WO2003049688A2 Bis hydrochloride monohydrate salt of rsv fusion inhibitor
06/19/2003WO2003049687A2 Medicinal compositions & therapeutic methods
06/19/2003WO2003049686A2 Stabilization of hypoxia inducible factor (hif) alpha
06/19/2003WO2003049685A2 Treatment for age-related macular degeneration
06/19/2003WO2003049682A2 Composition and method for treating chronic allograft rejection
06/19/2003WO2003049680A2 Compositions containing both sedative and non-sedative antihistamines
06/19/2003WO2003049679A2 Mitotic kinesin inhibitors
06/19/2003WO2003049678A2 Mitotic kinesin inhibitors
06/19/2003WO2003049676A2 Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
06/19/2003WO2003049675A2 Treating muscle wasting with selective androgen receptor modulators
06/19/2003WO2003049674A2 Method for treatment of enveloped viruses using jojoba oil esters
06/19/2003WO2003049673A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003WO2003049672A2 Methods and compositions for treating flavivirus-mediated disease
06/19/2003WO2003049668A2 Method of administering calcium citrate
06/19/2003WO2003049637A2 In situ bonds
06/19/2003WO2003049599A2 Methods and compositions for the diagnosis of asthma
1 ... 5430 5431 5432 5433 5434 5435 5436 5437 5438 5439 5440 5441 5442 5443 5444 5445 5446 5447 5448 5449 5450 ... 7860